Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-25T17:26:08.625Z Has data issue: false hasContentIssue false
  • English
  • Français

Integrating Symptomatic- and Disease-Modifying Treatments

Published online by Cambridge University Press:  07 November 2014

Jeffrey L. Cummings
Jeffrey L. Cummings*
Affiliation:
Dr. Cummings is Augustus S. Rose Professor of Neurology, professor of psychiatry and biobehavioral science, director of the Mary S. Easton Center for Alzheimer’s Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics at the David Geffen School of Medicine at the, University of California, Los Angeles
Get access Rights & Permissions [Opens in a new window]

Extract

Although treatments for Alzheimer’s disease (AD) currently focus on symptomatic therapies, we are entering into an era of disease-modifying therapies. Central to disease modification is early diagnosis; the disease should be slowed as early as possible, maximizing the preservation of cognitive integrity. Ideally, AD should be diagnosed before the onset of dementia, perhaps with the use of biomarkers.

Some therapies suggest that cholinesterase inhibitors and memantine have disease-modifying properties, though not all studies agree. Doody and colleagues have produced data suggesting that these agents may modify the course of AD, but it is not clear that they affect the underlying mechanisms that lead to cell death. Rather than being disease-modifying agents, cholinesterase inhibitors and memantine have potential as disease-course-modifying agents. Language precision will be extremely important in describing these therapies. One European consensus conference concluded that affecting disease course is not adequate for disease modification, but this has not been largely endorsed.

Symptomatic therapies are those affecting the course of the disease. Their benefits are multidimensional, improving cognition, global assessment, activities of daily living, behavior, and caregiver burden. Symptomatic therapies should defer decline. Clinical trials show that symptomatic therapies produce an initial improvement above baseline. However, some patients experience observable changes and some experience none. These therapies are believed to produce ~1 point improvement on the Mini-Mental State Examination (MMSE) average, and a decline that is otherwise parallel to a placebo group after a period of delayed progression (Slide 1).

Type
Research Article
Information
CNS Spectrums , Volume 13 , Issue S16 , 2008 , pp. 28 - 30
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Doody, R, Pavlik, V, Massman, P, et al.Changing patient characteristics and survival experience in an Alzheimer’s center patient cohort. Dement Geriatr Cogn Disord. 2005;20(2-3):198–208.Google Scholar
2.Doody, RS, Dunn, JK, Clark, CM, et al.Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2001;12(4):295–300.Google Scholar
3.Vellas, B, Andrieu, S, Sampaio, C, Coley, N, Wilcock, G; European Task Force Group. Endpoints for trials in Alzheimer’s disease: a European task force consensus. Lancet Neurol. 2008y;7(5):436–450.Google Scholar
4.Rogers, SL, Farlow, MR, Doody, RS, Mohs, R, Friedhoff, LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology. 1998;50(1):136–145.Google Scholar
5.Farlow, MR, Miller, ML, Pejovic, V. Treatment options in Alzheimer’s disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord. 2008;25(5):408–422.Google Scholar
6.Dubois, B, Feldman, HH, Jacova, C, et al.Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746.CrossRefGoogle ScholarPubMed
7.Apostolova, LG. Use of Magnetic Resonance Imaging to Identify Mild Cognitive Impairment. CNS Spectr. 2008;13:10(suppl 16):18–20.Google Scholar
8.Mintun, MA. FDG and Amyloid Positron Emission Tomography. CNS Spectr. 2008;13:10(suppl 16):21–24.Google Scholar
9.Twamley, EW, Ropacki, SA, Bondi, MW. Neuropsychological and neuroimaging changes in preclinical Alzheimer’s disease. J Int Neuropsychol Soc. 2006;12(5):707–735.CrossRefGoogle ScholarPubMed
10.Klunk, WE, Engler, H, Nordberg, A, et al.Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319.Google Scholar
11.Hansson, O, Zetterberg, H, Buchhave, P, et al.Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–234.Google Scholar